Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Dec 7;130(23):2447-2448.
doi: 10.1182/blood-2017-10-809673.

T-PLL: another check on the venetoclax list?

Prithviraj Bose  1 , Marina Y Konopleva  1
Affiliations
Comment

T-PLL: another check on the venetoclax list?

Prithviraj Bose et al. Blood. .

Abstract

In this issue of Blood, Boidol et al report a highly T-cell prolymphocytic leukemia (T-PLL)-specific response to the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax in an ex vivo high-throughput drug screen, as well as partial remissions (PRs) in 2 patients with relapsed/refractory (R/R) T-PLL and high disease burden, both of whom were previously treated with multiagent chemotherapy and alemtuzumab.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.Y.K. reports receiving research support from AbbVie and Genentech, and consulting fees from Roche, AbbVie, and Genentech. P.B. declares no competing financial interests.

Comment on

  • First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
    Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gültekin S, Hoermann G, Mayerhoefer ME, Hopfinger G, Hauswirth A, Panny M, Aretin MB, Hilgarth B, Sperr WR, Valent P, Simonitsch-Klupp I, Moriggl R, Merkel O, Kenner L, Jäger U, Kubicek S, Staber PB. Boidol B, et al. Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27. Blood. 2017. PMID: 28972014

References

    1. Boidol B, Kornauth C, van der Kouwe E, et al. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood. 2017;130(23):2499-2503. - PubMed
    1. Sud A, Dearden C. T-cell prolymphocytic leukemia. Hematol Oncol Clin North Am. 2017;31(2):273-283. - PubMed
    1. Kiel MJ, Velusamy T, Rolland D, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014;124(9):1460-1472. - PMC - PubMed
    1. Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58(9):1-17. - PMC - PubMed
    1. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-208. - PubMed

Publication types